Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics
ConditionChronic Widespread Pain
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-65
SponsorFlorida International University
About this trial
To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV
Eligibility criteria
Qualifiers
Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic
Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly likely to meet one or more
Disqualifiers
All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study
Non-HIV participants must be confirmed as HIV negative. HIV-negative participants with chronic widespread pain must self-report bodily pain more than once per week for at least three consecutive months and HIV-negative participants without chronic pain must self-report no pain, or pain less frequently than once per week for at least three consecutive months
Anemia
Current or past history of blood disorders which may increase hemolysis
Trial design
Treatments tested in this trial
- Relistor Injectable Product
Treatment groups
200 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov